You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Raising the Bar in Schizophrenia Care

  • Authors: Christoph U. Correll, MD; Jonathan Meyer, MD
  • CME / ABIM MOC / CE Released: 12/20/2022
  • Valid for credit through: 12/20/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    Nurses - 1.00 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), nurses, pharmacists, and other healthcare providers (HCPs) who provide care to patients with schizophrenia.

The goal of this activity is for learners to be better able to diagnose and manage patients with schizophrenia.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Emerging and novel treatments for patients with schizophrenia
  • Have greater competence related to
    • Integrating knowledge of metabolic comorbidities into treatment decision making for patients with schizophrenia


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Christoph U. Correll, MD

    Professor of Psychiatry and Molecular Medicine
    ​The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
    ​Hempstead, New York
    ​Investigator
    ​Center for Psychiatric Neuroscience
    ​Feinstein Institute for Medical Research
    ​Manhasset, New York

    Disclosures

    Christoph U. Correll, MD, has the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie, Inc.; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan; Angelini; Aristo; Boehringer Ingelheim Pharmaceuticals, Inc.; Cardio Diagnostics; Cerevel Therapeutics; CNX Therapeutics; Compass Pathways; CSL Seqirus; Damitsa; Gedeon Richter; Hikma Pharmaceuticals; Holmusk; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Karuna Therapeutics; LB Pharma; Lundbeck, Inc.; MedAvante-ProPhase; MedInCell; Merck Sharp & Dohme GmbH; Mindpax; Mitsubishi Tanabe Pharma Corporation; Mylan Laboratories Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Recordati; Relmada Therapeutics, Inc.; Reviva Pharmaceuticals Inc.; ROVI; SERVIER; SK Life Science; Sunovion Pharmaceuticals Inc.; Sun Pharmaceutical Industries, Ltd.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceuticals USA; Viatris Inc.
    Served as a speaker or a member of a speakers bureau for: AbbVie, Inc.; Angelini; Aristo; CSL Seqirus; Damitsa; Gedeon Richter; Hikma Pharmaceuticals; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Lundbeck, Inc.; Mitsubishi Tanabe Pharma Corporation; Mylan Laboratories Inc.; Otsuka Pharmaceutical Co., Ltd.; Recordati; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; Viatris Inc.
    Received grants for clinical research from: Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
    Contracted researcher for: Janssen Pharmaceuticals
    Stock options from: Cardio Diagnostics; LB Pharmaceuticals Inc; Mindpax

  • Jonathan Meyer, MD

    Clinical Professor
    Department of Psychiatry
    University of California San Diego
    La Jolla, California

    Disclosures

    Jonathan Meyer, MD, has the following relevant financial relationships:
    Served as an advisor or consultant for: ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Intra-Cellular Therapies, Inc.; Karuna Therapeutics; Neurocrine Biosciences, Inc.; Otsuka Pharmaceutical Co., Ltd.; Sunovion Pharmaceuticals Inc.; Teva Pharmaceuticals USA
    Served as a speaker or a member of a speakers bureau for: Alkermes, Inc.; Intra-Cellular Therapies, Inc.; Noven Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Teva Pharmaceuticals USA

Editor

  • Lisette Arnaud-Hevi, PhD

    Medical Education Director, Medscape, LLC 

    Disclosures

    Lisette Arnaud-Hevi, PhD, has no relevant financial relationships.  

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Raising the Bar in Schizophrenia Care

Authors: Christoph U. Correll, MD; Jonathan Meyer, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/20/2022

Valid for credit through: 12/20/2023, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Therapeutic Updates ​in Schizophrenia

How new treatments go beyond the theory of dopamine mediated dysfunction.
Christoph U. Correll, MD

Impact of Metabolic Comorbidities on Schizophrenia Management​: Clinically Challenging Case Discussions

Patients with schizophrenia lose 15 to 20 years of life due to cardiovascular diseases, but solutions exist.
Jonathan Meyer, MD
 

Educational Impact Challenge

The goal of this activity is for learners to be better able to diagnose and manage patients with schizophrenia.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print